Status:
UNKNOWN
Cancer-associated Gene Mutations in CML Treatment With TKIs by NGS
Lead Sponsor:
Nanfang Hospital, Southern Medical University
Conditions:
Different Gene Between Different TKIs Effection
Eligibility:
All Genders
18-70 years
Brief Summary
We performed targeted-capture sequencing of 127 known and putative cancer-related genes of patients who best effect to TKIs ,or intolerance to TKIs,or resistance to TKIs by next-generation sequencing ...
Eligibility Criteria
Inclusion
- Chronic myeloid leukemia-Chronic phase(CML-CP) patients treated with receiveTyrosine kinase inhibitor -TKI(including imatinib, dasatinib and nilotinib) for more than 1 years
- best effect to TKIs ,or intolerance to TKIs,or resistance to TKIs according to Q-pcr detected BCR/ABL(IS) in peripheral blood and hematologic response and cytogenetic response
- Informed consent of the patient or his legal representative
Exclusion
- Patients had history of CML-AP or CML-BC
- CML Patients who have received allogeneic hematopoietic stem cell transplantation
- CML Patients who have received immunotherapy (except interferon, including car-t and other cellular immunotherapy)
- Woman who is pregnant or nursing
Key Trial Info
Start Date :
February 16 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2022
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04274231
Start Date
February 16 2020
End Date
December 1 2022
Last Update
April 12 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
NanfangH
Guangzhou, Guangdong, China, 510515